Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria - Oligonucleotide Therapeutics Society

Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria

OTS

Clinical Development,Pre-Clinical Research,siRNA,Toxicology

November 10, 2020

SHARE

Post Views: 1,046

Badri P, Jiang X, Borodovsky A, Najafian N, Kim J, Clausen VA, Goel V, Habtemariam B, Robbie GJ.

Clin Pharmacokinet. 2020 Oct 13.

Related articles

Subscribe to our Newsletter

Oligonucleotide Therapeutics Society

Oligonucleotide Therapeutics Society

3960 W Point Loma Blvd, Suite H
Box 346
San Diego, CA 92110

info@oligotherapeutics.org

Terms & Conditions

Resources

Stay Connected

Search

Subscribe in a reader

© Copyright 2012 – 2024 | Oligotherapeutics.org | All Rights Reserved | Finfrock Marketing

Enter Username or Email Address:
Password:
Forgot Password | Sign Up

Save Password

First Name *
Last Name *
Username *
Email *
Password *
Confirm Password *
Phone:
Organization Name
Select Sectors

Reload
Already have an account? Login

This website uses cookies and third party services. Ok